Drug Discovery News: GigaGen CEO Dave Johnson, PhD, discusses I/O product development and impact of NIH grant support on company growth


The National Institutes of Health (NIH) is a household name in the drug discovery and development industry. Among the NIH’s many recipients is South San Francisco, Calif.-based GigaGen, a biotherapeutics company. GigaGen’s CEO, Dr. Dave Johnson, took some time to talk with us about how NIH funding and participation in the I-Corps commercialization program helped the company build momentum and secure additional funding and partner support.

Read the full story.